GLP-1 Medications 2026: A Las Vegas & Henderson Physician's Guide
The 2026 landscape of GLP-1 medications is the most competitive in weight management history. Patients considering medical weight loss in Las Vegas or Henderson now have multiple FDA-approved options and several investigational peptides. This guide explains the 2026 landscape — semaglutide, tirzepatide, retatrutide — and how a physician-led Las Vegas clinic chooses between them.
The 2026 GLP-1 landscape
The three medications that dominate patient conversations in 2026 are semaglutide (GLP-1 receptor agonist), tirzepatide (dual GLP-1/GIP agonist), and retatrutide (triple GLP-1/GIP/glucagon agonist). Semaglutide and tirzepatide are FDA-approved for chronic weight management. Retatrutide is under regulatory review and may be available for physician-supervised use through compounding pharmacies under federal and state regulations.
The right choice for an individual patient depends on BMI, prior weight loss attempts, comorbidities, medical history, current medications, lab work, and goals. There is no universal first-line answer.
How a physician-led Las Vegas clinic evaluates you
At our Las Vegas peptide clinic, the choice between GLP-1 medications is made after a complete medical evaluation with Dr. Charles Kamen, MD. The $88 evaluation includes a clinical consultation, lab work, and a goal-based discussion.
We do not auto-prescribe the highest-dose version of any medication. We do not promise specific weight loss results. We design protocols individually and supervise your care over time. If GLP-1 therapy is not appropriate, you get that answer directly.
What to expect from a 2026 GLP-1 evaluation
The evaluation is the most important part of the process. It includes a clinical consultation with Dr. Kamen, review of your medical history and current medications, ordering of a comprehensive lab panel, and a goal-based discussion.
After labs return, Dr. Kamen reviews the results with you and designs a protocol if indicated. The protocol may include peptide therapy, NAD+, prescription weight-loss medications, hormone optimization, IV therapy, or targeted lifestyle changes — but only after evaluation and only when medically appropriate.
The 2026 GLP-1 landscape at a glance
- Semaglutide: single GLP-1 receptor agonist, FDA-approved for weight management
- Tirzepatide: dual GLP-1/GIP agonist, FDA-approved for weight management
- Retatrutide: triple GLP-1/GIP/glucagon agonist, under regulatory review
- Choice depends on patient — not medication preference or marketing
- All three require physician supervision, lab monitoring, and lifestyle support
Frequently asked questions
Which GLP-1 medication is right for me in 2026?
There is no universal first-line answer. The right choice depends on your body, your history, your goals, and your response over time. A physician-led evaluation in Las Vegas can help. See our <a href="/peptide-clinic-las-vegas">Las Vegas peptide clinic</a> page to schedule.
How much do GLP-1 medications cost in Las Vegas?
Protocol costs depend on the medication, dose, and your individualized plan. The initial medical evaluation is $88. See our <a href="/blog/peptide-therapy-cost-las-vegas">peptide therapy cost in Las Vegas guide</a>.
Do you serve Henderson patients for GLP-1 therapy?
Yes. Most of our weight management patients come from Henderson, Green Valley, Anthem, and Seven Hills. See our <a href="/peptide-clinic-henderson">Henderson peptide clinic page</a>.
The 2026 GLP-1 landscape gives Las Vegas patients more options than ever — and more opportunities to choose the wrong clinic. The right next step is a complete medical evaluation by a physician who designs protocols individually. Schedule at our Las Vegas peptide clinic or our Henderson peptide clinic.
References
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216.
- Wilding JPH, et al. NEJM. 2021;384(11):989-1002.
- Jastreboff AM, et al. NEJM. 2023;389(6):514-525.